Literature DB >> 12399255

Contributions of heart rate and contractility to myocardial oxygen balance during exercise.

Patrice Colin1, Bijan Ghaleh, Xavier Monnet, Jinbo Su, Luc Hittinger, Jean-Francois Giudicelli, Alain Berdeaux.   

Abstract

The respective contributions of heart rate (HR) reduction and left ventricular (LV) negative inotropy to the effects of antianginal drugs are debated. Accordingly, eight instrumented dogs were investigated during exercise at spontaneous and paced HR (250 beats/min) after administration of either saline, atenolol, or ivabradine (selective pacemaker current channel blocker). During exercise, atenolol and ivabradine (both 1 mg/kg iv) similarly reduced HR (-30% from 222 +/- 5 beats/min), and LV mean ejection wall stress was not altered. LV dP/dt(max) was reduced by atenolol but not ivabradine. Diastolic time (DT) was increased by atenolol versus saline (195 +/- 6 vs. 123 +/- 4 ms, respectively) and to a greater extent by ivabradine (233 +/- 11 ms). Myocardial oxygen consumption (MVo(2)) was lower under ivabradine and atenolol versus saline (6.7 +/- 0.6 and 4.7 +/- 0.4 vs. 8.1 +/- 0.6 ml/min, respectively, P < 0.05). Under pacing, DT and MVo(2) were similar between ivabradine and saline but significantly reduced with atenolol. Thus HR reduction and negative inotropy equally contribute to the reduction in MVo(2) during exercise in the normal heart. The negative inotropy limits the increase in DT afforded by HR reduction.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12399255     DOI: 10.1152/ajpheart.00564.2002

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  31 in total

Review 1.  Heart rate: a forgotten link in coronary artery disease?

Authors:  Kim M Fox; Roberto Ferrari
Journal:  Nat Rev Cardiol       Date:  2011-04-26       Impact factor: 32.419

2.  Heart rate reduction by inhibition of If or by beta-blockade has different effects on postsystolic wall thickening.

Authors:  L Lucats; B Ghaleh; P Colin; X Monnet; A Bizé; A Berdeaux
Journal:  Br J Pharmacol       Date:  2006-12-18       Impact factor: 8.739

3.  Pharmacodynamic effects of ivabradine, a negative chronotropic agent, in healthy cats.

Authors:  Richard E Cober; Karsten E Schober; Tony C A Buffington; Xiaobai Li; Sabine C Riesen; John D Bonagura
Journal:  J Vet Cardiol       Date:  2011-10-24       Impact factor: 1.701

Review 4.  The effects of heart rate control in chronic heart failure with reduced ejection fraction.

Authors:  Dario Grande; Massimo Iacoviello; Nadia Aspromonte
Journal:  Heart Fail Rev       Date:  2018-07       Impact factor: 4.214

5.  Acute ivabradine treatment reduces heart rate without increasing atrial fibrillation inducibility irrespective of underlying vagal activity in dogs.

Authors:  Kazunori Uemura; Masashi Inagaki; Can Zheng; Toru Kawada; Meihua Li; Masafumi Fukumitsu; Masaru Sugimachi
Journal:  Heart Vessels       Date:  2016-11-14       Impact factor: 2.037

6.  Chronic heart rate reduction with ivabradine improves systolic function of the reperfused heart through a dual mechanism involving a direct mechanical effect and a long-term increase in FKBP12/12.6 expression.

Authors:  Nicolas Couvreur; Renaud Tissier; Sandrine Pons; Valérie Chetboul; Vassiliky Gouni; Patrick Bruneval; Chantal Mandet; Jean-Louis Pouchelon; Alain Berdeaux; Bijan Ghaleh
Journal:  Eur Heart J       Date:  2009-12-21       Impact factor: 29.983

7.  β-Blockers and ivabradine differentially affect cardiopulmonary function and left ventricular filling index.

Authors:  Ulrich Fischer-Rasokat; Jörg Honold; Denise Lochmann; Sebastian Wolter; Christoph Liebetrau; Stephan Fichtlscherer; Helge Möllmann; Ioakim Spyridopoulos; Christian W Hamm
Journal:  Clin Res Cardiol       Date:  2015-12-19       Impact factor: 5.460

Review 8.  Preclinical results with I(f) current inhibition by ivabradine.

Authors:  Alain Berdeaux
Journal:  Drugs       Date:  2007       Impact factor: 9.546

Review 9.  Sympathetic Activation in Chronic Heart Failure: Potential Benefits of Interventional Therapies.

Authors:  Kamila Lachowska; Marcin Gruchała; Krzysztof Narkiewicz; Dagmara Hering
Journal:  Curr Hypertens Rep       Date:  2016-07       Impact factor: 5.369

10.  Ivabradine: the evidence of its therapeutic impact in angina.

Authors:  Guillaume Marquis-Gravel; Jean-Claude Tardif
Journal:  Core Evid       Date:  2008-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.